SEC Filing Summary: Predictive Oncology Inc. (POAI)
Business Context and Reporting Period
This Form 8-K Current Report, dated February 18, 2025, details a registered direct offering by Predictive Oncology Inc. (POAI). The transaction closed on February 19, 2025. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol POAI.
Key Financial Metrics and Transaction Details
- Shares Sold: 363,336 shares of Common Stock.
- Purchase Price: $1.50 per share.
- Gross Proceeds: Approximately $545,004.
- Use of Proceeds: Working capital and general corporate purposes.
- Placement Agent Fees: 7.0% of gross proceeds plus a 1.0% management fee, totaling 8.0% of gross proceeds, plus $15,000 for legal fees and expenses.
- Placement Agent Warrants: Warrants issued to purchase up to 25,434 shares (7.0% of shares sold) at an exercise price of $1.875 per share (125% of purchase price), exercisable for five years.
Material Changes and Restrictions
The filing discloses a material definitive agreement regarding the sale of equity. The company has agreed to restrictions on the issuance and sale of Common Stock or Common Stock Equivalents for a 5-day period following the closing. Additionally, restrictions on variable rate transactions apply for one year after closing, subject to certain exceptions. The filing does not provide comparative financial data (revenue, profit, cash flow, or debt levels) as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds for working capital and general corporate purposes. The filing includes standard legal disclaimers noting that representations and warranties in the Purchase Agreement are for the benefit of the parties and do not characterize the actual condition of the company. The company has a 12-month tail and right of first refusal agreement with the placement agent, H.C. Wainwright & Co., LLC.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8.0% placement agent fees and $15,000 in legal expenses.
- Confirm the dilution impact of the 363,336 new shares and the potential 25,434 warrant shares on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and exceptions to the lock-up restrictions.
- Check the company's latest 10-K or 10-Q for current cash balances and burn rate to assess the sufficiency of the $545,004 gross proceeds for stated working capital needs.
- Monitor the press releases (Exhibits 99.1 and 99.2) for any additional strategic context regarding the capital raise.